Author: David Khayat Publisher: Springer Science & Business Media ISBN: 2817809203 Category : Medical Languages : en Pages : 260
Book Description
This is the fourth volume of our series Progress in Anti-cancer Therapy. For the past four years we have taken the challenge to select each year, some of the most interesting topics on the wide field of oncology. As usual, this volume continues the tradition and covers five cancers (breast, prostate, bladder, lym phoma and ovarian), the role of HIV and HTLV in cancer, as well as some deve lopmental pharmacology and behavioral issues. This year, we have particularly focused our attention on one of the most com mon (although rarely addressed) cancer accounting for more than 315,00 newly diagnosed cases and 41,000 cancer-related deaths annually (Landis SH et al., 1999) : prostate cancer. Five chapters address some of the issues concerning this disease. The chap ter by Schroder describes the hopes and pitfalls of early detection of prostate cancer. It reviews the literature on screening studies that have been performed both in the US and in Europe. These studies suggest that cancer mortality could be reduced by screening for prostate cancer, mostly through PSA testing. However, the effectiveness of early detection still needs to be definitely confir med and ongoing randomized studies are described, the results of which will probably help the medical community determine the worth of PSA-based scree ning for prostate cancer. On the same hand, the paper from von Eschenbach is reviewing the clinical problems that are related this disease.
Author: Gabriel N. Hortobagyi Publisher: Springer Science & Business Media ISBN: 2817809181 Category : Medical Languages : en Pages : 383
Book Description
This is the third volume of our series Progress in Anti-Cancer Chemo therapy. Following the strategy of the first two volumes, it covers selected aspects of progress in this fast moving field of Oncology, with contribu tions from some of the world's best known leaders in both basic and clin ical research. This year we focused on seven areas: Three prominent Clinical investigators reviewed conceptual advances in cancer research. Dr Buzdar presented a history and overview of the protection of human subjects who participate in clinical research, and the mechanisms developed to assure the ethical conduct of research on human beings. Frei reviewed an exciting and rapidly moving area of che motherapy of solid tumors, including a cogent discussion of the issues related to dose-intensification. Fisher summarized conceptual advances in our therapeutic approach to breast cancer and the paradigm shifts that lead us to our current management strategies. From this summary he pro jected breast cancer research into the future, a daunting task under any circumstance. Fundamental research in cancer biology has been responsible for our improved understanding of the development and progession of malignant disease. Such understanding will lead to improved diagnosis, therapy, and eventually, prevention. Isaacs reviews the area of hereditary breast cancer, a topic undergoing rapid transformation and with mUltiple impli cations in the daily practice of medicine. Fidler, an international expert in metastasis research reviews the potential utility of angiogenesis inhib itors in research and the therapeutic ramifications.
Author: Robert F. Ozols Publisher: Springer Science & Business Media ISBN: 1461538726 Category : Medical Languages : en Pages : 314
Book Description
The importance of drug resistance in cancer chemotherapy cannot be over stated. The 500,000 patients who die every year from cancer in the United States have, in most cases, been treated with chemotherapy. Many of these patients responded initially to chemotherapy, but death resulted from the development of drug-resistant tumors. In the first volume in the series. Drug Resistance in Chemotherapy the results of comprehensive laboratory studies aimed at understanding the mechanisms for resistance to individual agents and to the development of broad cross-resistance were described. In the past 2 years there has been substantial progress in understanding the molecular biology associated with these mechanisms of drug resistance. For the first time we are starting to understand which mechanisms are playing an im portant role in human tumors, and even more importantly, clinical trials have recently been initiated in an effort to reverse specific forms of drug resistance. The purpose of this volume is to describe the new advances, both at the molecular level and in the clinic regarding mechanisms of drug resistance and potential ways this resistance can be circumvented. This volume is focused upon mechanisms of resistance associated with two major classes of anticancer drugs: alkylating agents (including cisplatin) and the natural products (e. g. , adriamycin and vinblastine). The first section of the book describes new insights into the genetic mechanisms associated with drug resistance.
Author: Kyu-Won Kim Publisher: Springer ISBN: 9402408444 Category : Medical Languages : en Pages : 286
Book Description
The reader will discover a comprehensive and multifaceted overview of the history of the development of anticancer drugs deeply influenced by the cell concept of cancer and future directions for the development of new anticancer drugs. First, this book documents the scientific progress in biological science over the last 70 years and the influence this progress had in cancer research. Summaries and charts of important discoveries complete this overview. Furthermore, this book outlines the process of anticancer drug development with a focus on the characteristic drug groups of each era, related to advancements of chemistry and biological sciences. This book also provides brief mechanism of action of drugs, illustrated by comprehensive timelines and conceptual cartoons. This book finally sums up the limitations of the current anticancer drug development and seeks new directions for anticancer drug discovery, considering under the systemic view of cancer.
Author: Atta-ur-Rahman Publisher: Bentham Science Publishers ISBN: 1681080583 Category : Medical Languages : en Pages : 280
Book Description
“Frontiers in Anti-Cancer Drug Discovery” is an Ebook series devoted to publishing the latest and the most important advances in Anti-Cancer drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The Ebook series should prove to be of interest to all pharmaceutical scientists involved in research in Anti-Cancer drug design and discovery. Each volume is devoted to the major advances in Anti-Cancer drug design and discovery. The Ebook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field. The fifth volume of the series features chapters on the following topics: -Nutraceuticals and natural food products for cancer treatment -Pharmacogenomics in Anti-cancer treatment -Cancer stem cells -Potassium channel targeting for brain tumor treatment -Sorafenib in the management of hepatocellular carcinoma …and more.
Author: Robert A. Parsons Publisher: Nova Publishers ISBN: 9781600218224 Category : Medical Languages : en Pages : 240
Book Description
One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100 percent effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anti-cancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information on how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.
Author: Franco M. Muggia Publisher: Springer Science & Business Media ISBN: 1461325633 Category : Medical Languages : en Pages : 280
Book Description
As in CANCER CHEMOTHERAPY 1, this volume brings to the reader highlights in three different areas of cancer therapeutics: new concepts and models; drug classes; and clinical settings. Topics were chosen because of their timeliness or probable current impact in cancer treatment. Authors were selected on the basis of their ability to provide a critical overview of specific subjects and their involvement in original work. I shall review the aims of this second volume, and then elaborate on the scope of its con tents. The principal aim of the volumes on cancer chemotherapy in the' Cancer Treatment and Research' series, as stated in the preface to the first volume, is to assemble in a concentrated form selected ingredients of chemothera peutic progress. These ingredients are to include concepts in therapeutic strategy, pre-clinical studies, development of major classes of compounds, identificatlon of new directions and of landmarks of clinical progress. Thus we do not foresee overlap with series which provide an yearly update of chemotherapy in an encyclopedic manner, or reviews of cancer chemother apy. Unlike those publications, our volumes are not intended to seek a place in shelves as a reference manual. It is this Editor's hope that persons repre senting various biomedical disciplines will seek the' Cancer Treatment and Research' chemotherapy volumes to survey advances in the field at regular intervals.
Author: David Khayat
Author: Gabriel N. Hortobagyi
Author: 
Author: Robert F. Ozols
Author: 
Author: David Khayat
Author: Kyu-Won Kim
Author: Atta-ur-Rahman
Author: Robert A. Parsons
Author: Franco M. Muggia